Sandoz plans to build a Biosimilar Technical Development Center in Slovenia
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
The agreement extends the customer's suite of cloud DevOps, data engineering, and data platform management solutions
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Subscribe To Our Newsletter & Stay Updated